

Data Sheet

 Product Name:
 MK-4074

 Cat. No.:
 CS-0029249

 CAS No.:
 1039758-22-9


 Molecular Formula:
 C33H31N3O6

Target: Acetyl-CoA Carboxylase

Pathway: Metabolic Enzyme/Protease

Solubility: DMSO: 83.3 mg/mL (147.27 mM; Need ultrasonic)

565.62



BIOLOGICAL ACTIVITY:

Molecular Weight:

MK-4074 is a liver-specific inhibitor of **acetyl-CoA carboxylase** ACC1 and ACC2 with **IC**₅₀ values of approximately 3 nM. IC50 & Target: IC50: 3 nM (Acetyl-CoA Carboxylase)^[1] **In Vitro**: MK-4074 strongly inhibits both ACC1 and ACC2 with IC₅₀ values of approximately 3 nM. MK-4074 is highly liver specific because it is a substrate of organic anion transport protein (OATP) transporters that are present only in hepatocytes, and excretion of MK-4074 from hepatocytes into bile is dependent on the MRP2 efflux transporter^[1]. **In Vivo**: In male KKAy mice, a mouse model of obesity, type 2 diabetes, and fatty liver, a single oral dose of MK-4074 (0.3-3 mg/kg) significantly decreases DNL in a dose-dependent manner with an ID₅₀ value of 0.9 mg/kg 1 hr post-administration. In a time course study, MK-4074 orally at 30 mg/kg reduces hepatic DNL by 83%, 70%, and 51% at 4, 8, and 12 hr post-dose, respectively. Single oral doses of MK-4074 at 30 and 100 mg/kg significantly increases plasma total ketones, a surrogate biomarker for hepatic FAO, by 1.5-fold to 3-fold for up to 8 hr^[1].


PROTOCOL (Extracted from published papers and Only for reference)

Kinase Assay: ^[1]Recombinant ACC protein is purified from FM3A or Sf9 cells expressing recombinant ACC by chelating chromatography or from liver by Softlink avidin resin chromatography. Purified ACC protein is incubated with MK-4074 in assay buffer containing 5 mM ATP, 250 mM acetyl-CoA, 4.1 mM NaHCO₃, 0.086 mM NaH₁₄CO₃, 20 mM potassium citrate, 20 mM MgCl₂, 2 mM DTT, 0.5 mg/mL BSA and 50 mM HEPES-Na (pH 7.5) for 40 min at 37°C^[1]. Cell Assay: ^[1]For cellular assays of DNL and FAO, cells are pre-incubated with MK-4074 for 1 hr. Then the cells are incubated for additional 1-3 hr with either 65-260 mM ¹⁴C-labeled acetate or 0.018 mM ³H-labeled palmitate for DNL or FAO assay, respectively. After incubation, intracellular ¹⁴C-labeled lipids and released ³H-labeled fatty acids are extracted and measured for DNL and FAO, respectively^[1]. Animal Administration: MK-4074 is prepared in water^[1]. ^[1]Mice^[1]

Studies are performed in male KKAy mice or C57BL/6J mice. KKAy mice are fed a chow diet while C57BL/6J mice are fed a high-fat diet (45% fat) for 3 weeks prior to study. Mice are treated for 7 days with vehicle (distilled water, 0.2 mL/mouse) before MK-4074 administration to acclimate mice to oral dosing. Animals are drug naive at the time of study. Mice are housed individually. Male KKAy mice (n=10-11/group) are administered a single oral dose of MK-4074 (0.3 to 3 mg/kg) prior to liver slice studies. Male KKAy mice (n=5/group) are administered a single oral dose of MK-4074 (3 to 30 mg/kg) prior to measurement of liver DNL rates. Male KKAy mice (n=8/group) are administered a single oral dose of MK-4074 (10 to 100 mg/kg) and plasma ketone bodies are measured at the indicated times. Male C57BL/6J mice (n=5, veh; n=10, MK-4074) are fed chow or a high-fat/high-sucrose (HF/HS) diet for 7 weeks and vehicle or MK-4074 is administered orally (10 or 30 mg/kg/day) for 4 weeks prior to study^[1].

References:

Page 1 of 2 www.ChemScene.com



CAIndexNames:

 $3-Pyridine carboxylic\ acid,\ 5-[1'-[(1-cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-3, 4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]-1, 4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-1, 4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-1, 4-dihydro-4-oxospiro[2H-1-benzopyran$

SMILES:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com